Src family kinases are involved in the regulation of a wide variety of normal cellular signal transduction pathways, such as cell growth, differentiation, survival, adhesion and migration. Considerable evidence implicates elevated expression and/or activity of Src kinases in many human cancers, osteoporosis, cardiovascular disorders and immune system dysfunction; thus, this family of protein tyrosine kinases now exists as intriguing targets for both basic research and drug discovery. Herein, a number of examples of currently developed Src family kinase inhibitors in selected patents from 2002 - 2005 will be described. Special attention will be made to the chemical diversity of ATP binding site inhibitors, potency, selectivity and therapeutic application of the compounds.
No takes yet. Share an insight, caveat, or question.
Parang et al. (2005) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: